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Objective. To compare effectiveness, side effects, and patients’ perception of vaginal misoprostol versus intravenous sulprostone
for ending pregnancy after fetal death between 14 and 42 weeks gestation. Method. Multicenter randomized controlled trial, using
block randomization, central allocation, and prior power analysis. Outcome measures. Induction-delivery interval, gastrointestinal
side effects, use of analgesia, pain perception, pyrexia, placental retention, hemorrhage, and women’s opinions. Results. Of 176
women aimed for, 143 were randomized over 7 years, of whom 4 were excluded. There was no difference in delivery within 24
and 36 hours: 91.4% and 97.1% with misoprostol (n = 70) versus 85.5% and 92.8% with sulprostone (n = 69). There was
no difference in either gastrointestinal side effects, as reported by the women and their caregivers, use of analgesia, women’s
pain perception, blood loss or placental retention. Hyperthermia ≥38◦C was more common with misoprostol (24.3%) than with
sulprostone (11.6%; difference: +12.7%; 95% CI: +1.2% to +25.3%) and related to the total dose used. Acceptability of both
induction methods was similar except for freedom of movement, which was substantially in favor of misoprostol (lack of freedom
reported with misoprostol in 34.3% versus 63.8% with sulprostone; difference:−29.5%; 95% CI:−13.6% to−45.4%). Conclusions.
Misoprostol and sulprostone are similarly effective with little difference in side effects except for hyperthermia, related to the dose
of misoprostol used, and women’s reported lack of mobility with intravenous sulprostone. Effectiveness of both methods increased
with gestational age.
Copyright © 2009 Kristin Van Mensel et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Intrauterine fetal death is a rare event after the first
trimester of pregnancy. Retention of the dead fetus may cause
consumptive coagulopathy, but this is a rare complication
occurring after a prolonged retention of several weeks [1, 2].
As there is rarely a medical need to end the pregnancy,
the emotional distress of carrying a dead baby is usually
the sole reason for intervention in such circumstances. It
is important that the intervention not only achieves what
it aims to achieve but also does so with as little distress
and discomfort as possible. Traditional induction methods,
such as amniotomy and oxytocin, are notoriously ineffective,
particurlarly at low gestational ages as there is a 20-fold
difference in oxytocin sensitivity between mid-pregnancy
and term [3, 4]. As reviewed by Keirse [5], before the
advent of prostaglandins [6], inducing labor after early fetal
death was frequently an ordeal for both the patient and
her caregivers. Of the many treatments used, high doses of
oxytocin were the most effective [7], but these nearly always
led to some degree of water retention [8], often requiring
the treatment to be spread over several days to avoid its
consequences [5]. Combining the use of oxytocin with
amniotomy could reduce the induction-expulsion interval,
but exposed the woman to infection, particularly when the
treatment was ineffective [9].
Prostaglandins and prostaglandin analogues are known
to be effective, even more effective after fetal death than
they are in pregnancies with a live fetus at similar pregnancy
duration [5, 10, 11]. However, in the doses required well
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before term, they are associated with unpleasant side effects
especially of the gastrointestinal tract [12–14]. Sulprostone
is a PGE2 analogue with a greater uteroselectivity than the
parent compound [15] and, therefore, fewer gastrointestinal
side effects. At the time this study was started, it was
the most commonly used agent for induction of labour
after fetal death in the Netherlands, with its dose regimen
for that indication well established from a randomized
controlled trial [14]. We compared this treatment with
sulprostone, a PGE2 analogue registered for obstetric use,
with the use of misoprostol, a PGE1 analogue. Although not
registered for obstetric use and marketed for the prevention
and treatment of gastroduodenal ulcers, misoprostol was
becoming widely used for a variety of obstetric indications
and was purported to cause, in the doses required, fewer
systemic side effects than other prostaglandin preparations.
A multicenter randomized controlled trial was initiated to
evaluate the relative merits of misoprostol and sulprostone.
2. Patients and Methods
All women with a fetal death between 14 and 42 weeks of
gestation at one of 12 participating hospitals were eligible
for the study provided they were not in labor, had no
placental abruption, no problems of communication, and
gave informed consent. The study protocol was approved by
the ethical committee.
The 1 to 1 randomization sequence was computer gen-
erated in blocks of 10 and 20. Randomization was centrally
controlled and allocation was by phoning the central unit
where a serially numbered, sealed, opaque envelope was
opened for each participant. While concealment of allocation
was ensured, once allocated no attempt was made to blind
women or caregivers to the actual treatment, as this would
have required additional placebo interventions in all women
either intravenously or vaginally.
Sulprostone was administered intravenously, as pre-
viously evaluated in a randomized controlled trial [14],
at 1 μg/min (1 ampoule of 500 μg sulprostone in 250 mL
NaCl 0.9%, at 30 mL/min) for 36 hours or until fetal and
placental expulsion, if this occurred earlier. As this low
dose was administered by continuous intravenous infusion,
no adjustment for gestational age was deemed necessary
[14]. Misoprostol doses, on the other hand, were based on
gestational age: 400 μg between 14 and 26 weeks, 100 μg
between 27 and 36 weeks, and 50 μg between 37 and 42
weeks. While adjusting doses of misoprostol according to
gestational age corresponds with the known increase in uter-
ine sensitivity to prostaglandins with advancing gestation [5]
and has become common practice since [16], this regimen
was based on anecdotal evidence at the time. Misoprostol
was administered in the posterior vaginal fornix at 4-hourly
intervals up to a maximum of 4 doses per 24 hours or
until labor was established. Intravenous oxytocin was started
if augmentation of labor was deemed necessary. In both
treatment arms women were switched to the other regimen
after 36 hours, if complete expulsion had not occurred within
36 hours after the start of treatment.
Gastrointestinal side effects, severe vomiting and diar-
rhea in particular, were the primary outcomes of interest.
Sample size was determined on the basis of an anticipated
4-fold reduction in the frequency of these side effects from
20% in the sulprostone group [14] to 5% with misoprostol.
This required 76 patients per group given an α error of 0.05
(two-sided) and a β error of 0.2. We anticipated to recruit 88
women per group to allow for a 15% drop-out or switching
to the alternative treatment. Induction-delivery interval,
use of analgesia, estimated blood loss, need for additional
intervention, and measures of maternal satisfaction were the
other predetermined outcome measures.
Side effects, pain, nausea, vomiting, and diarrhea, were
scored independently by the midwife caring for the woman
and by the women themselves. Midwives monitored side
effects during the procedure and scored these on the basis
of the perceived need for and use of additional medications.
Thus, pain was scored as no pain relief needed, mild oral
analgesics, intramuscular narcotics, and epidural analgesia.
Nausea and vomiting were scored as no nausea, light no
drugs required, need for antiemetics, and vomiting not
remedied by antiemetics. Diarrhea was similarly scored as
no diarrhea, light no drugs required, and severe enough to
warrant medication.
Women scored side effects independently after having
left the labor ward. Pain experience was scored on a visual
analogue scale from zero to ten. Women also indicated what
pain relief they had received and whether they had to wait
too long for pain relief. Nausea and diarrhea were expressed
on a scale from zero to three (none, light, average, or heavy).
Vomiting was scored as yes or no and the number of episodes.
Women’s opinions were also sought on whether they had felt
restricted in their mobility, how they assessed the duration
of the procedure and whether they were generally satisfied or
would have preferred another management.
Differences in outcome between groups were assessed
with the chi-square test and confidence interval (CI) analysis.
3. Results
Only 143 of the a priori determined number of 176 women
were randomized over a period of 7 years, before recruitment
was stopped. Cessation of recruitment was prompted by the
fact that even without formal data analysis, clinicians in most
centers had become increasingly convinced of the superiority
of misoprostol over sulprostone to the extent that they could
no longer justify randomization between the two treatments.
Four of the 143 women (2.8%) were excluded from the
analysis (Figure 1). One, assigned to misoprostol, withdrew
her consent after randomization. Case notes were lost for 3
others (1 in the misoprostol and 2 in the sulprostone group)
and it could not be ascertained whether they actually had or
had not received the allocated treatment or had given birth
spontaneously. One woman in the misoprostol group was
started on the alternative treatment to what she had been
allocated. She was retained in her assigned group. Baseline
characteristics of the 139 women remaining in the study are
shown in Table 1.
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Figure 2: Cumulative delivery rate in women assigned to vaginal
misoprostol (closed circles) or intravenous sulprostone (open
circles).
The median induction-delivery interval was 2 hours
shorter with misoprostol than with sulprostone (Table 2,
Figure 2), but the difference was compatible with chance.
Including one woman in the sulprostone group, who was
switched to misoprostol before the scheduled 36 hours
because of pronounced dilatation of the antecubital vasa
vasorum, the need to resort to the alternative treatment
before complete expulsion, was similar in both groups (4.3%
with misoprostol versus 8.7% with sulprostone; difference:
−4.4%; 95% CI: −12.6% to +3.8%). So was the use of
additional oxytocic agents (difference: +4.0%; 95% CI:
−10.5% to +18.4%; Table 2). The frequency of placental
retention for 1 hour or more (difference: +4.1%; 95% CI:
−8.7% to +16.8%) and the need for curettage or manual
exploration (difference: +3.8%; 95% CI:−11.9% to +19.5%)
were also similar in both groups (Table 2).
Table 1: Baseline characteristics (number) of the women included
in the analysis.
Characteristic Misoprostol Sulprostone
(n = 70) (n = 69)
Age (mean, SD) 30.3 (5.2) 30.3 (4.8)
<20 years 2 1
≥35 years 10 13
Parity
Nulliparous 29 30
Parity ≥ 5 3 2





<22 weeks 38 34
22–27 weeks 10 11
28–36 weeks 17 16




Duration of fetal death
<48 hours 21 19
≥28 days 6 2
Inaccurate 28 31
Condition of cervix∗
Closed (dilatation 0 cm) 55/69 51/68
Length ≥ 3 cm 31/68 25/66
Length ≥ 2 cm 59/68 57/66
Ruptured membranes 5 1
Fetal weight
<500 g 39 34
500–2,499 g 19 19
≥2,500 g 8 6
Not recorded 4 10
∗Cervical length or dilatation were not recorded for all women.
Placental retention, whilst not related to treatment
allocation, was clearly associated with low gestational age. Of
25 women with placental retention for >1 hour (14 in the
misoprostol and 11 in the sulprostone group; Table 2), 23
were under 22 weeks. Placental retention occurred in 32% of
women (23 of 72) under 22 weeks compared with less than
5% (2 of 43) at 28 weeks or more (difference: 27%; 95% CI:
14.8% to 39.8%). Similarly, 42 of 47 women who required
curettage or manual removal were under 28 weeks. Overall
60% (42 of 70) of women in the misoprostol group had
the placenta delivered spontaneously within 1 hour without
curettage or manual removal as compared to 63.8% in the
sulprostone group (difference −3.8%; 95% CI: −19.9% to
+12.4%; Table 2).
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Table 2: Labor and delivery outcomes.
Outcome∗ Misoprostol Sulprostone
(n = 70) (n = 69)
n % n %
Induction-delivery interval (hours)
Median 10.4 12.3
Range 1.7–58.0 2.0 – 74.8
10th–90th centile 4.5–22.0 5.8 – 31.3
Induction-delivery interval
Within 12 hours 41 58.6 34 49.3
Within 24 hours 64 91.4 59 85.5
Within 36 hours 68 97.1 64 92.8
Within 48 hours 69 98.6 67 97.1
Switched to alternative treatment 3 4.3 6 8.7
Use of other uterotonics 19 27.1 16 23.2
Before delivery 6 3
After delivery 13 13
Placental retention> 1 hour 14 20.0 11 15.9
Curettage or manual removal of placenta 25 35.7 22 31.9
Placenta delivered spontaneously within
1 hour without curettage or manual
removal
At < 22 weeks 15/38 39.5 15/3 444.1
At 22–27 weeks 8/10 80.0 9/11 81.8
At ≥ 28 weeks 18/21 85.7 18/22 81.8
All women∗∗ 42/70 60.0 44/69 63.8
Blood loss (mL)
<300 mL 43 61.4 43 62.3
≥500 mL 15 21.4 14 20.3
≥1,000 mL 5 7.1 6 8.6
Blood transfusion 1 1.4 3 4.3
∗
None of the differences between the two groups reaches statistical significance.
∗∗Includes 3 women (1 misoprostol and 2 sulprostone) with too uncertain a duration of pregnancy to be classified in the gestational age categories.
Whilst postpartum hemorrhage of 1000 mL or more
occurred in 8% (11 of 139) with no difference between
the two groups (Table 2), blood transfusion was given to
one woman treated with misoprostol and three treated with
sulprostone (difference: −2.9%; 95% CI: −8.4% to +2.6%).
Our prior hypothesis of a lower rate of gastrointestinal
side effects among misoprostol treated women was not
confirmed. Gastrointestinal side effects, whether reported
by the caregivers (Table 3) or by the women (Table 4),
occurred with a similar frequency and similar severity in
both groups. There are indications for a difference in the
perception of gastrointestinal side effects between women
and their caregivers. Whereas 10% of the women in the
misoprostol group found that they had severe nausea and
15.7% reported several episodes of vomiting, only 4.3% had
received antiemetic treatment. Comparable figures in the
sulprostone group were, respectively, 2.9%, 15.9%, and 8.7%.
Severe diarrhea was reported by 1.4% of the women in the
misoprostol group and 2.9% in the sulprostone group, but
1.4% of the women in the misoprostol and 5.8% in the
sulprostone group received medication for it. Hyperthermia,
defined as a temperature of 38◦C or more, occurred twice as
frequently in the misoprostol group than in the sulprostone
group (24.3% versus 11.6%; difference: +12.7%; 95% CI:
+1.2% to +25.3%; P < .05). Hyperthermia occurred in
15.6% of women (7 of 45) who received less than 1000 μg
misoprostol, but in 40% (10 of 25) of those receiving 1000 μg
or more (P < .05).
We also considered the severity of side effects in a
composite outcome consisting of either one of the following:
hyperthermia, and women’s report of either more than
one episode of vomiting, severe nausea or moderate or
severe diarrhea. This occurred in 30 women (42.9%) in the
misoprostol group and 19 (27.5%) in the sulprostone group
(difference: +15.3%; 95% CI: 0.0% to +31.0%; P > .05).
There was no difference between the misoprostol and
sulprostone group in the use of analgesia and women’s pain
scores. There was a marked difference in women’s reported
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Table 3: Frequency of side effects as recorded by the caregivers.
Outcome∗ Misoprostol Sulprostone
(n = 70) (n = 69)
n % n %
Nausea and vomiting
None 53 75.7 54 78.3
All nausea/vomiting 5 7.1 8 11.6
Mild, unmedicated 2 2.9 2 2.9
Medicated 3 4.3 6 8.7
Not recorded 12 17.1 7 10.1
Diarrhea
None 61 87.1 62 89.9
All diarrhea 7 10.0 7 10.1
Mild, unmedicated 6 8.6 3 4.3
Medicated 1 1.4 4 5.8
Not recorded 2 2.9 0 0
Use of analgesia
None 12 17.1 10 14.5
Any pain relief 57 81.4 59 85.5
Mild analgesics 11 15.7 10 14.5
Opiates 14 20.0 12 17.4
Epidural 29 41.4 33 47.8
Opiates and epidural 3 4.3 4 5.8
Not recorded 1 1.4 0 0
Hyperthermia (≥38.0◦C)∗ 17 24.3 8 11.6
∗
None of the differences are statistically significant except for the frequency of hyperthermia (Chi square test: P < .05).
lack of mobility (“some restriction” and “too restricted”
combined) between the misoprostol (34.3%) and the sulpro-
stone (63.8%) groups (difference: −29.5%; 95% CI: −13.6%
to −45.4%; P < .05) in favor of misoprostol. Women’s
opinion on the acceptability of the procedure (82.9% in the
misoprostol and 89.9% in the sulprostone group; difference:
−7.0%; 95% CI: −18.3% to +4.4%), though, did not differ
between the 2 groups. Overall satisfaction (91.4% in the
misoprostol and 88.4% in the sulprostone group; difference:
+3.0%; 95% CI: −7.0% to +13.0%), and preference for the
other method (4.3% in the misoprostol and 8.7% in the
sulprostone group; difference: −4.4%; 95% CI: −12.6% to
+3.8%) were also slightly, but not significantly, in favor of
misoprostol.
4. Discussion
When this study was initiated, sulprostone was well estab-
lished in the Netherlands as a highly effective method
for ending pregnancy after fetal death [14] but causing
gastrointestinal side effects in 20%. We, therefore, required
a substantial reduction in side effects to warrant the use
of another prostaglandin analogue, misoprostol, which is
not registered for obstetric use. As misoprostol is marketed
for the prevention and treatment of gastroduodenal ulcers
[17], it was anticipated that misoprostol would have less
side effects with perhaps almost equal effectiveness. This
did not materialize neither in the women’s perception nor
in the reports of their caregivers. If anything, all significant
side effects combined were more frequent with misoprostol
than with sulprostone. The only single significant difference
related to hyperthermia and this occurred twice as frequently
with misoprostol than with sulprostone. Notwithstanding
this, during the trial clinicians clearly gained the impression
that misoprostol was better tolerated and more effective
than sulprostone. As a result there was increasing reluctance
to randomize between the two treatments, which led to
termination of the trial before its target was reached and
before an objective assessment could be made. It would seem,
therefore, that a number of intangible items colored the clin-
icians’ perception. These may well include the ease of vaginal
administration compared with the need for an intravenous
line, women’s perception of freedom of movement, and
other factors that were not assessed. In comparison with the
women themselves clinicians also tended to underestimate
both the frequency and the severity of gastrointestinal side
effects, but this occurred in both treatment groups and not
to such an extent that it reached statistical significance.
In terms of effectiveness, we found no substantial differ-
ences between the two treatments as applied here (Table 2;
Figure 2), although the median induction-delivery interval
was 2 hours shorter with misoprostol than with sulprostone.
In both groups a few women were switched to the alternative
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Table 4: Women’s assessment of the treatments and their side effects.
Outcome∗ Misoprostol Sulprostone
(n = 70) (n = 69)
n % n %
Nausea
None 44 62.9 41 59.4
All nausea 23 32.9 25 39.1
Light, 14 20.0 17 24.6
Moderate 2 2.9 6 8.7
Severe 7 10.0 2 2.9
Not reported 3 4.3 3 4.3
Vomiting
None 50 71.4 49 71.0
All vomiting 17 24.3 17 24.6
Only once 5 7.1 6 8.7
Several episodes 11 15.7 11 15.9
Not reported 4 5.7 3 4.3
Diarrhea
None 56 80.0 56 81.2
All diarrhea 11 15.7 10 14.5
Light, 6 8.6 7 10.1
Moderate 4 5.7 1 1.4
Severe 1 1.4 2 2.9
Not reported 3 4.3 3 4.3
Pain score (range 0 to 10)
Median (interquartile range) 5 (3–7) 5 (2–7)
Women’s perception of the duration
of induction
Too long 10 14.3 14 20.3
Not too long 26 37.1 26 37.7
Uncertain 31 44.3 26 37.7
Not answered 3 4.3 3 4.3
Women’s opinion on restriction of
movement∗
Felt no restriction 40 57.1 22 31.9
Any restriction 24 34.3 44 63.8
Some restriction 21 30.0 36 52.2
Too restricted 3 4.3 8 11.6
Not answered 6 8.6 3 4.3
Women’s opinion on the
acceptability of the procedure
Very acceptable 34 48.6 23 33.3
Acceptable 24 34.3 39 56.5
Poor acceptability 7 10.0 4 5.8
Not answered 5 7.1 3 4.3
Women’s overall satisfaction
Very satisfied 50 71.4 50 72.5
Satisfied 14 20.0 11 15.9
Little or not at all 2 2.9 3 4.3
Not answered 4 5.7 5 7.2
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Table 4: Continued.
Outcome∗ Misoprostol Sulprostone
(n = 70) (n = 69)
n % n %
Would have preferred the other
method
Yes 3 4.3 6 8.7
No 39 55.7 30 43.5
Do not know 23 32.9 30 43.5
Not answered 5 7.1 3 4.3
∗
There was no statistical difference in outcome between the two groups except for restriction of movement (Chi square test; P < .005).
treatment, but this occurred less frequently than had been
anticipated and more than 90% of women delivered within
36 hours, with no difference between treatments as allocated.
While expulsion of the dead fetus occurred spontaneously in
all women, there was a high incidence of placental retention
and one third received either a manual removal or a curettage
(Table 2). Incomplete expulsion, placental retention, and
the need for curettage or manual exploration were equally
common in both groups and clearly linked to the duration
of pregnancy. Under 20 weeks of gestation, 60% of women
had either placental retention for more than one hour or a
uterine evacuation whilst this occurred in only 15% of those
beyond 20 weeks.
A limitation of our study is that we cannot be certain
to have used equipotent doses of both agents. While our
sulprostone regimen was based on data from a previous
controlled trial [14], no such information was available to
determine the optimal dose of misoprostol. Even pharma-
cokinetic data on vaginal misoprostol were lacking at the
time. Several such studies have become available since [18–
22]. Although based on first trimester pregnancies and not
entirely in agreement with each other, they are reasonably
consistent in showing a large individual variation among
women, with peak levels being reached on average about
one hour after vaginal misoprostol administration, which
then decrease gradually over a period of several hours. Low
levels of misoprostol acid seem to remain present in serum
for at least 6 hours, although uterine activity has mostly
declined by that time [21]. Even now, dose regimens of
misoprostol used for termination of pregnancy differ widely
among published reports and there is little solid information
that relates to intrauterine fetal death in particular [16, 23].
Yet, it has been known for more than 25 years [5] that
prostaglandins and prostaglandin analogues have a higher
uterotonic potency after fetal death than in live pregnancies
of the same duration thereby permitting the use of lower
doses [5]. This has been confirmed more specifically for
misoprostol too [24, 25]. On the other hand, the occurrence
of uterine hypertonus is less problematic in such pregnancies,
which may explain why doses used to end pregnancy after
fetal death have usually not been lower than those used for
live pregnancies of similar duration. However, this approach
may well increase the frequency of unpleasant side effects
which form an additional burden for women who are heavily
challenged already by the fetal demise. While we found no
evidence for a difference in side effects between our different
misoprostol regimens at different gestational ages, side effects
and hyperthermia in particular did relate to the total doses
used. It has been argued that the incidence of side effects
correlates reasonably well with serum levels while the uterine
effects seem to relate more to the duration than to the height
of serum levels above a particular, but as yet not clearly
defined, threshold [22].
There is only one other published comparison of miso-
prostol and sulprostone for terminating pregnancy after fetal
death [25]. In that study vaginal misoprostol, 100 μg every
12 hours, was compared with historical controls receiving
intravenous sulprostone at 1 μg per minute at gestational
ages between 15 and 38 weeks. Whilst the median induction-
delivery interval in the sulprostone group (12.3 hours) was
identical to that observed in our study, in the misoprostol
group it was 16.5 hours compared with 10.4 hours in our
study. This, combined with more recent pharmacokinetic
data [22], would suggest that the dose regimen used in that
study was less adequate than ours, possibly because of the
long interval between doses or the lack of differentiation
between earlier and later gestations. Nevertheless, that study
too concluded that misoprostol was the better of the two
options with no significant differences in either effectiveness
or side effects.
5. Conclusions
Our study found no evidence for a marked difference in side
effects between the two treatments, although such difference
seemed to exist in the clinicians’ subjective perception during
the course of the trial. There was no difference in the use of
analgesia or in women’s pain perception. Hyperthermia was
more common in the misoprostol group. Both treatments
scored the same in terms of gastrointestinal side effects, but,
in the women’s assessments, other elements of inconvenience
associated with the induction of labor and especially freedom
of movement were in favor of misoprostol. Although not
formally assessed in this study, the cost differential is also
largely in favor of misoprostol. Given that both treatments
were equally effective, misoprostol would seem to be the
preferred management option, albeit that further research
may still establish more optimal dose regimens at different
gestational ages than that used here.
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